WallStSmart
TARA

Protara Therapeutics Inc

NASDAQ: TARA · HEALTHCARE · BIOTECHNOLOGY

$5.33
+3.09% today

Updated 2026-04-30

Market cap
$273.67M
P/E ratio
P/S ratio
EPS (TTM)
$-1.34
Dividend yield
52W range
$3 – $8
Volume
1.0M

Protara Therapeutics Inc (TARA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20122013201420152016201720182019202020212022202320242025
Revenue$2.95M$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)-100.0%
Cost of revenue$57000.00$27000.00$57000.00$123000.00$148000.00$115000.00$16000.00$196000.00$1.17M$247000.00$341000.00$332000.00$362000.00
Gross profit$-57000.00$-27000.00$2.95M$-57000.00$-123000.00$-148000.00$-115000.00$-16000.00$-196000.00$-1.17M$-247000.00$-341000.00$-332000.00$-362000.00
Gross margin100.0%
R&D$5.91M$3.99M$6.43M$12.38M$18.87M$21.69M$15.51M$6.44M$11.88M$21.09M$16.81M$24.79M$31.70M$42.63M
SG&A$4.10M$8.49M$9.84M$105989.00$10.57M$8.82M$22.46M$26.40M$20.74M$18.62M$17.45M$21.92M
Operating income$-8.00M$-7.12M$-7.58M$-20.87M$-28.70M$-30.36M$-26.08M$-15.25M$-34.44M$-47.49M$-67.06M$-43.61M$-49.15M$-64.55M
Operating margin-257.1%
EBITDA$-7.91M$-7.02M$-2.46M$-21.32M$-28.40M$-29.82M$-20.61M$-7.81M$-33.78M$-45.40M$-64.57M$-43.27M$-48.82M$-64.19M
EBITDA margin-83.3%
EBIT$-7.97M$-7.05M$-2.48M$-21.38M$-28.53M$-29.96M$-20.73M$-7.83M$-33.98M$-45.52M$-64.81M$-43.61M$-49.15M$-64.55M
Interest expense$861000.00$857000.00$144000.00$193000.00$259000.00$0.00$0.00$34000.00$1.74M$1.14M$4.17M
Income tax$5.09M$-363000.00$372000.00$657000.00$5.35M$-262000.00$-466000.00$-117000.00$-1.14M$-341000.00
Effective tax rate0.0%0.0%290.6%1.7%-1.3%-2.2%-26.6%1.7%1.4%0.2%1.7%0.8%0.0%0.0%
Net income$-7.97M$-7.91M$-3.34M$-21.38M$-28.53M$-29.96M$-25.44M$-14.99M$-33.98M$-47.25M$-65.95M$-40.42M$-44.60M$-57.44M
Net income growth (YoY)+0.7%+57.8%-539.6%-33.4%-5.0%+15.1%+41.1%-126.6%-39.1%-39.6%+38.7%-10.3%-28.8%
Profit margin-113.4%